<sup>18</sup>F-FDG PET/CT显像在胃癌分期及治疗方案制定中的应用价值

朱娅华; 邓玮玮; 范敏; 郑文璐; 张春银; 朱娅华; 邓玮玮; 范敏; 郑文璐; 张春银

doi:10.3760/cma.j.issn.1673-4114.2018.01.003

[1]

尤徐阳, 贺锋, 徐巧玲, 等. ¹⁸F-FDG PET/CT同机序贯增强CT在胃癌治疗前分期中的价值[J].中华核医学与分子影像杂志, 2016, 36(4):315-321. DOI:10.3760/cma.j.issn.2095-2848. 2016. 04.009.
You XY, He F, Xu QL, et al. Sequential ¹⁸F-FDG PET/CT and contrast-enhanced CT in the pretreatment staging of gastric cancer[J]. Chin J Nucl Med Mol Imaging, 2016, 36(4):315-321. doi: 10.3760/cma.j.issn.2095-2848.2016.04.009

[2]

Xu H, Guo R, Xu W, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography scan after gastric endoscopy in those who present with non-specific symptoms, is it necessary or not?[J]. South Asian J Cancer, 2017, 6(2):59-63. DOI:10.4103/2278-330X.208853.

[3]

陈凛, 卢灿荣.新版日本胃癌"处理规约"和"治疗指南"之解读[J].临床外科杂志, 2012, 20(1):10-14. DOI:10.3969/j.issn.1005-6483.2012.01.005.
Chen B, Lu CR. Interpretation of the new version of gastric cancer in Japan "Processing protoco" and "treatment guidelines"[J]. J Clin Surg, 2012, 20(1):10-14. doi: 10.3969/j.issn.1005-6483.2012.01.005

[4]

金民山, 张俊, 姜一逸, 等. ¹⁸F-FDG PET/CT在不明原发灶肿瘤中的临床应用价值[J].国际放射医学核医学杂志, 2017, 41(2):94-97, 149. DOI:10.3760/cma.j.issn.1673-4114.2017.02.003.
Jin MS, Zhang J, Jiang YY, et al. Clinical value of ¹⁸F-FDG PET/CT in cancer of unknown primary[J]. Int J Radiat Med Nucl Med, 2017, 41(2):94-97, 149. doi: 10.3760/cma.j.issn.1673-4114.2017.02.003

[5]

Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas:correlation with endoscopic and histopathological findings[J]. Eur J Nucl Med Mol Imaging, 2003, 30(2):288-295. DOI:10.1007/s00259-002-1029-5.

[6]

Chen R, Zhou X, Liu J, et al. Relationship between ¹⁸F-FDG PET/CT findings and HER2 expression in gastric cancer[J]. J Nucl Med, 2016, 57(7):1040-1044. DOI:10.2967/jnumed.115.171165.

[7]

Tian J, Chen L, Wei B, et al. The value of vesicant ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) in gastric malignancies[J]. Nucl Med Commun, 2004, 25(8):825-831. DOI:10.1097/01.mnm.0000135042.54461.f6.

[8]

Mochiki E, Kuwano H, Katoh H, et al. Evaluation of ¹⁸F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer[J]. World J Surg, 2004, 28(3):247-253. DOI:10.1007/s00268-003-7191-5.

[9]

Fonocho E, Aydin N, Reddy S, et al. Limitations in the use of ¹⁸F-FDG PET in the pre-operative staging of gastric cancer:A case series[J]. Int J Surg Case Rep, 2017, 36:147-150. DOI:10.1016/j.ijscr.2017. 05.026.

[10]

Yamada A, Oguchi K, Fukushima M, et al. Evaluation of 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography in gastric carcinoma:relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression[J]. Ann Nucl Med, 2006, 20(9):597-604. doi: 10.1007/BF02984657

[11]

Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer[J]. Eur J Surg Oncol, 2009, 35(5):449-455. DOI:10.1016/j.ejso.2008.11.010.

[12]

Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013:featured updates to the NCCN Guidelines[J]. J Natl Compr Canc Netw, 2013, 11(5):531-546. DOI:10.6004/jnccn.2013.0070.

[13]

Ozkan E, Araz M, Soydal C, et al. The role of ¹⁸F-FDG-PET/CT in the preoperative staging and posttherapy follow up of gastric cancer:comparison with spiral CT[J]. World J Surg Oncol, 2011, 9:75. DOI:10.1186/1477-7819-9-75.

[14]

Shin JA, Park JW, An M, et al. Diagnostic accuracy of ¹⁸F-FDG positron emission tomography for evaluation of hepatocellular carcinoma[J]. Korean J Hepatol, 2006, 12(4):546-552.

[15]

Imamura H, Kurokawa Y, Kawada J, et al. Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer:results of a randomized controlled trial[J]. World J Surg, 2011, 35(3):625-630. DOI:10.1007/s00268-010-0914-5.

[16]

Fujita J, Kurokawa Y, Sugimoto T, et al. Survival benefit of bursectomy in patients with resectable gastric cancer:interim analysis results of a randomized controlled trial[J]. Gastric Cancer, 2012, 15(1):42-48. DOI:10.1007/s10120-011-0058-9.

[17]

Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:the MUNICON phase Ⅱ trial[J]. Lancet Oncol, 2007, 8(9):797-805. DOI:10.1016/S1470-2045(07)70244-9.